GSK-3 Represses Growth Factor-inducible Genes by Inhibiting NF-κB in Quiescent Cells

par Graham, Julie R., Tullai, John W., Cooper, Geoffrey M.
Publié 2010

A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells

par Tullai, John W, Graham, Julie R, Cooper, Geoffrey M
Publié 2011

mRNA Degradation Plays a Significant Role in the Program of Gene Expression Regulated by Phosphatidylinositol 3-Kinase Signaling

par Graham, Julie R., Hendershott, Melissa C., Terragni, Jolyon, Cooper, Geoffrey M.
Publié 2010

Prolyl Isomerase Pin1 Regulates Transcription Factor LSF (TFCP2) by Facilitating Dephosphorylation at Two Serine-Proline Motifs

par Saxena, Utsav H., Owens, Laura, Graham, Julie R., Cooper, Geoffrey M., Hansen, Ulla
Publié 2010

AP-1 Is a Component of the Transcriptional Network Regulated by GSK-3 in Quiescent Cells

par Tullai, John W., Tacheva, Silvia, Owens, Laura J., Graham, Julie R., Cooper, Geoffrey M.
Publié 2011

Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NF...

par Adams Kenneth W, Graham Julie R, Terragni Jolyon, Schaffer Michael E, Tullai John W, Cooper Geoffrey M
Publié 2008-01-01

Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NF...

par Terragni, Jolyon, Graham, Julie R, Adams, Kenneth W, Schaffer, Michael E, Tullai, John W, Cooper, Geoffrey M
Publié 2008

The E-box Binding Factors Max/Mnt, MITF, and USF1 Act Coordinately with FoxO to Regulate Expression of Proapoptotic and Cell Cycle Control Genes by Phosphatidylinositol 3-Kinase/Ak...

par Terragni, Jolyon, Nayak, Gauri, Banerjee, Swati, Medrano, Jose-Luis, Graham, Julie R., Brennan, James F., Sepulveda, Sean, Cooper, Geoffrey M.
Publié 2011

Serine Protease HTRA1 Antagonizes Transforming Growth Factor-β Signaling by Cleaving Its Receptors and Loss of HTRA1 In Vivo Enhances Bone Formation

par Graham, Julie R., Chamberland, Angela, Lin, Qingcong, Li, X. Jian, Dai, David, Zeng, Weilan, Ryan, Mark S., Rivera-Bermúdez, Moisés A., Flannery, Carl R., Yang, Zhiyong
Publié 2013

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

par Vinayak, Shaveta, Tolaney, Sara M., Schwartzberg, Lee, Mita, Monica, McCann, Georgia, Tan, Antoinette R., Wahner-Hendrickson, Andrea E., Forero, Andres, Anders, Carey, Wulf, Gerburg M., Dillon, Patrick, Lynce, Filipa, Zarwan, Corrine, Erban, John K., Zhou, Yinghui, Buerstatte, Nathan, Graham, Julie R., Arora, Sujata, Dezube, Bruce J., Telli, Melinda L.
Publié dans JAMA Oncol (2019)

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

par Konstantinopoulos, Panagiotis A., Waggoner, Steven, Vidal, Gregory A., Mita, Monica, Moroney, John W., Holloway, Robert, Van Le, Linda, Sachdev, Jasgit C., Chapman-Davis, Eloise, Colon-Otero, Gerardo, Penson, Richard T., Matulonis, Ursula A., Kim, Young Bae, Moore, Kathleen N., Swisher, Elizabeth M., Färkkilä, Anniina, D’Andrea, Alan, Stringer-Reasor, Erica, Wang, Jing, Buerstatte, Nathan, Arora, Sujata, Graham, Julie R., Bobilev, Dmitri, Dezube, Bruce J., Munster, Pamela
Publié dans JAMA Oncol (2019)

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

par Färkkilä, Anniina, Gulhan, Doga C., Casado, Julia, Jacobson, Connor A., Nguyen, Huy, Kochupurakkal, Bose, Maliga, Zoltan, Yapp, Clarence, Chen, Yu-An, Schapiro, Denis, Zhou, Yinghui, Graham, Julie R., Dezube, Bruce J., Munster, Pamela, Santagata, Sandro, Garcia, Elizabeth, Rodig, Scott, Lako, Ana, Chowdhury, Dipanjan, Shapiro, Geoffrey I., Matulonis, Ursula A., Park, Peter J., Hautaniemi, Sampsa, Sorger, Peter K., Swisher, Elizabeth M., D’Andrea, Alan D., Konstantinopoulos, Panagiotis A.
Publié dans Nat Commun (2020)

Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

par Färkkilä, Anniina, Gulhan, Doga C., Casado, Julia, Jacobson, Connor A., Nguyen, Huy, Kochupurakkal, Bose, Maliga, Zoltan, Yapp, Clarence, Chen, Yu-An, Schapiro, Denis, Zhou, Yinghui, Graham, Julie R., Dezube, Bruce J., Munster, Pamela, Santagata, Sandro, Garcia, Elizabeth, Rodig, Scott, Lako, Ana, Chowdhury, Dipanjan, Shapiro, Geoffrey I., Matulonis, Ursula A., Park, Peter J., Hautaniemi, Sampsa, Sorger, Peter K., Swisher, Elizabeth M., D’Andrea, Alan D., Konstantinopoulos, Panagiotis A.
Publié dans Nat Commun (2020)